Login to Your Account



Amgen doubles down on RNAi in potential $673.5M Arrowhead deal

By Marie Powers
News Editor

Thursday, September 29, 2016

Amgen Inc. took a global exclusive license, with an option on a second, to develop and commercialize cardiovascular treatments using the subcutaneous RNAi delivery platform developed by Arrowhead Pharmaceuticals Inc.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription